Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Key Points

• Basilea Pharmaceutica AG experienced a significant increase in short interest, jumping 223.4% from 4,700 shares to 15,200 shares in August.
• The company's stock opened at $67.75, reaching a one-year high of the same price, with a low of $47.50.
• Basilea Pharmaceutica focuses on addressing unmet medical needs in oncology and anti-infectives, with its notable product being the antifungal drug Cresemba.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 15,200 shares, an increase of 223.4% from the August 15th total of 4,700 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days. Currently, 0.1% of the company's shares are sold short. Currently, 0.1% of the company's shares are sold short. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Basilea Pharmaceutica Stock Performance

Basilea Pharmaceutica stock remained flat at $67.75 during trading on Tuesday. The company has a 50 day moving average price of $65.70 and a two-hundred day moving average price of $57.04. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.85 and a quick ratio of 4.16. Basilea Pharmaceutica has a 1-year low of $47.50 and a 1-year high of $67.75.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.